{"published":"2026-06-27 20:31:21","url":"https://kleineschwarzekatze.hatenablog.com/entry/2026/06/27/203121","author_url":"https://blog.hatena.ne.jp/KleineSchwarzeKatze/","image_url":null,"description":"\u3053\u306e\u8a18\u4e8b\u3067\u306f\u3001Federal Register\u306eSUPPLEMENTARY INFORMATION\u306e\u3046\u3061\u3001FDA\u304c\u3069\u306e\u3088\u3046\u306a\u4e8b\u5b9f\u95a2\u4fc2\u3092\u524d\u63d0\u3068\u3057\u3066\u3044\u308b\u306e\u304b\u3092\u6574\u7406\u3059\u308b\u3002\u4ee5\u4e0b\u306b1\u6b21\u8cc7\u6599\u3092\u793a\u3059\u3002https://www.federalregister.gov/documents/2026/04/30/2026-08455/chemocentryx-inc-proposal-to-withdraw-approval-of-new-drug-application-for-tavneos-avacopan-capsule\u3053\u3053\u3067\u306f\u3001FDA\u306e\u8a55\u4fa1\u304c\u59a5\u5f53\u304b\u3069\u3046\u304b\u3001Amgen/ChemoCentryx\u5074\u306e\u53cd\u8ad6\u304c\u6210\u308a\u2026","blog_title":"\u9ed1\u732b\u7684\u6c34\u6676\u7403~\u4ffa\u306e\u6c34\u6676\u7389","width":"100%","provider_name":"Hatena Blog","type":"rich","blog_url":"https://kleineschwarzekatze.hatenablog.com/","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fkleineschwarzekatze.hatenablog.com%2Fentry%2F2026%2F06%2F27%2F203121\" title=\"1.2 FDA\u306b\u3088\u308bTAVNEOS\u627f\u8a8d\u64a4\u56de\u63d0\u6848\u3092\u8aad\u3080(2)\uff1aFDA\u306e\u4e3b\u5f35\u306e\u8981\u7d04 - \u9ed1\u732b\u7684\u6c34\u6676\u7403~\u4ffa\u306e\u6c34\u6676\u7389\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","provider_url":"https://hatena.blog","height":"190","categories":["\u30bf\u30d6\u30cd\u30aa\u30b9","\u81e8\u5e8a\u958b\u767a"],"author_name":"KleineSchwarzeKatze","title":"1.2 FDA\u306b\u3088\u308bTAVNEOS\u627f\u8a8d\u64a4\u56de\u63d0\u6848\u3092\u8aad\u3080(2)\uff1aFDA\u306e\u4e3b\u5f35\u306e\u8981\u7d04","version":"1.0"}